Tirelli U, Zagonel V, Serraino D, Thomas J, Hoerni B, Tangury A, Ruhl U, Bey P, Tubiana N, Breed W P
Division of Radical Oncology, Centro di Riferimento Oncologica Aviano, Italy.
J Clin Oncol. 1988 Nov;6(11):1708-13. doi: 10.1200/JCO.1988.6.11.1708.
The results of a European Organization for Research and Treatment of Cancer (EORTC) retrospective study on non-Hodgkin's lymphoma (NHL) in elderly patients (greater than or equal to 70 years of age) seen in Europe in 1984 are reported. A precodified form was sent to 55 European institutes in order to evaluate the incidence of NHL in the elderly with regard to natural history, treatment-related toxicity, response, and survival. Thirteen institutes participated in the study. One hundred thirty-seven cases of NHL were observed in the elderly during 1984, making up 28% of the total number of NHL seen in those institutes. The median age was 77 years; 21% of the patients had favorable (low-grade) and 73% unfavorable (intermediate- and high-grade) histology, according to the Working Formulation. Stage at presentation was localized (I and II) in 60% and advanced in 37% of the patients. Most of the physicians used standard therapy regimens at reduced doses, from the beginning of the treatment. Sixty patients (44%) underwent a "conservative" treatment (one or two antineoplastic drugs or local field radiotherapy) and 77 (56%) an "aggressive" treatment (polychemotherapy regimens or extended field radiotherapy). Response was similar between the two treatment groups, but severe and lethal toxicity was significantly higher among patients treated with aggressive therapy. Prospective randomized studies are clearly needed to define the optimal treatment in elderly patients with advanced unfavorable NHL.
本文报告了欧洲癌症研究与治疗组织(EORTC)针对1984年在欧洲就诊的老年患者(年龄大于或等于70岁)非霍奇金淋巴瘤(NHL)的一项回顾性研究结果。一份预先编码的表格被发送至55家欧洲机构,以便评估老年NHL患者在自然病史、治疗相关毒性、反应及生存方面的发病率。13家机构参与了该研究。1984年在老年患者中观察到137例NHL病例,占这些机构所诊治NHL病例总数的28%。中位年龄为77岁;根据工作分类法,21%的患者组织学类型为预后良好(低级别),73%为预后不良(中级别和高级别)。就诊时分期为局限性(I期和II期)的患者占60%,晚期患者占37%。大多数医生从治疗开始就采用降低剂量的标准治疗方案。60例患者(44%)接受了“保守”治疗(一种或两种抗肿瘤药物或局部野放疗),77例患者(56%)接受了“积极”治疗(联合化疗方案或扩大野放疗)。两个治疗组的反应相似,但积极治疗组患者的严重和致命毒性明显更高。显然需要进行前瞻性随机研究来确定晚期预后不良老年NHL患者的最佳治疗方案。